Harrow (HROW) Share-based Compensation Growth (3y) (2013 - 2026)
Harrow (HROW) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.35% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 24.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.84% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 88.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 23.49% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 11.76% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 20.51% |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 32.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.94% |
| Dec 31, 2025 | -13.08% |
| Sep 30, 2025 | 19.17% |
| Jun 30, 2025 | -24.00% |
| Mar 31, 2025 | 63.84% |
| Dec 31, 2024 | 31.36% |
| Sep 30, 2024 | 37.22% |
| Jun 30, 2024 | 58.24% |
| Mar 31, 2024 | 69.57% |
| Dec 31, 2023 | 81.61% |
| Sep 30, 2023 | 69.63% |
| Jun 30, 2023 | 105.02% |
| Mar 31, 2023 | 45.24% |
| Dec 31, 2022 | 52.26% |
| Sep 30, 2022 | 195.34% |
| Jun 30, 2022 | 75.77% |
| Mar 31, 2022 | 9.55% |
| Dec 31, 2021 | 269.28% |
| Sep 30, 2021 | 41.26% |
| Jun 30, 2021 | 21.03% |